The G Protein-Coupled Estrogen Receptor (GPER) is a novel membrane-bound receptor that mediates non-genomic actions of the primary female sex hormone 17β-estradiol. Studies over the past two decades have elucidated the beneficial actions of this receptor in a number of cardiometabolic diseases. This review will focus specifically on the cardiac actions of GPER, since this receptor is expressed in cardiomyocytes as well as other cells within the heart and most likely contributes to estrogen-induced cardioprotection. Studies outlining the impact of GPER on diastolic function, mitochondrial function, left ventricular stiffness, calcium dynamics, cardiac inflammation, and aortic distensibility are discussed. In addition, recent data using genetic mouse models with global or cardiomyocyte-specific GPER gene deletion are highlighted. Since estrogen loss due to menopause in combination with chronological aging contributes to unique aspects of cardiac dysfunction in women, this receptor may provide novel therapeutic effects. While clinical studies are still required to fully understand the potential for pharmacological targeting of this receptor in postmenopausal women, this review will summarize the evidence gathered thus far on its likely beneficial effects.Copyright © 2020 Groban, Tran, Ferrario, Sun, Cheng, Kitzman, Wang and Lindsey.
Basophil Sensitivity Reflects the Long-term Clinical Outcome of Subcutaneous Immunotherapy in Grass Pollen Allergic Patients.
March 9, 2020
Colorectal cancer patients with promotor heterogeneous and homogeneous methylation display different prognosis.
October 29, 2020
[Workplace and Work-Related Return to Work Interventions for Employees with Common Mental Disorders: Between Health-Promoting Organisational Development and Self-Management].
September 3, 2020
February 25, 2020
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.